S-1/A: Citius Oncology Launches Public Offering to Fund LYMPHIR Commercialization Amidst Severe Financial Strain and Going Concern Warning

Citius Oncology, Inc. is offering up to 5,319,149 shares of common stock and accompanying warrants to raise an estimated $13.65 million to fund the commercialization of its FDA-approved oncology drug LYMPHIR, despite significant financial challenges and a going concern warning.

Summary

• Citius Oncology is offering up to 5,319,149 shares of common stock and accompanying warrants, along with pre-funded warrants, at an assumed combined offering price of $2.82 per share and warrant.
• The estimated net proceeds from this offering are approximately $13.65 million, which will primarily be used for the commercialization of LYMPHIR, including milestone and royalty payments, and for working capital and general corporate purposes.
• LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of persistent or recurrent Cutaneous T-cell Lymphoma (CTCL), received FDA approval in August 2024.
• The company reported a net loss of $7,735,552 for the quarter ended March 31, 2025, and an accumulated deficit of $53,673,344 as of the same date.
• As of March 31, 2025, cash and cash equivalents stood at a mere $112, with a negative working capital of approximately $31.7 million.
• Significant outstanding liabilities include $28.4 million in license payments (to Dr. Reddys and Eisai) and $16.4 million owed to third-party suppliers and manufacturers.
• A payment schedule has been agreed with Eisai, requiring $2,535,318 by July 15, 2025, followed by four monthly payments of $2,350,000, and a final payment of $2,197,892 by December 15, 2025, with 2% annual interest.
• A $3,800,111 promissory note issued to Citius Pharma is repayable in full if the gross proceeds from this offering meet or exceed $10 million.
• The company is heavily reliant on Citius Pharma for funding and operational support through an Amended and Restated Shared Services Agreement.
• Preliminary Phase 1 trial results for LYMPHIR in combination with pembrolizumab for recurrent solid tumors showed an overall response rate (ORR) of 27% (4 out of 15 evaluable patients) and a clinical benefit rate (CBR) of 33% (5 out of 15 evaluable patients).
• LYMPHIR was included in the National Comprehensive Cancer Network (NCCN) guidelines with a Category 2A recommendation in September 2024.
• The company successfully regained compliance with Nasdaq's minimum bid price rule on June 26, 2025.
• The total number of authorized common stock shares was increased from 110,000,000 to 410,000,000 on April 7, 2025.

Sentiment

Score: 3

Explanation: While FDA approval for LYMPHIR and promising preliminary clinical data for its combination therapy are positive developments, the company faces severe financial distress, including a going concern warning, extremely low cash reserves, and substantial liabilities. Its ability to commercialize its only approved product and sustain operations is highly dependent on successful future financing, which remains uncertain. The current offering is primarily a stop-gap measure to address immediate financial obligations rather than a robust growth funding round.

Positives

• FDA approval of LYMPHIR in August 2024 for persistent or recurrent CTCL, providing a key product for commercialization.
• The company estimates an attractive and growing market for LYMPHIR, projected to exceed $400 million, which is currently underserved by existing treatments.
• Preliminary Phase 1 trial results for LYMPHIR in combination with pembrolizumab for recurrent solid tumors demonstrated an overall response rate (ORR) of 27% and a clinical benefit rate (CBR) of 33%, with notable efficacy in patients who had failed prior checkpoint inhibitors.
• LYMPHIR's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines with a Category 2A recommendation in September 2024 is expected to facilitate coverage and reimbursement from the Centers for Medicare and Medicaid Services (CMS).
• The company has secured supply agreements with two cGMP-compliant third-party manufacturing facilities, indicating readiness for commercial production.
• Regained compliance with Nasdaq's minimum bid price rule on June 26, 2025, resolving a potential delisting issue.
• The executive management team possesses significant prior experience in pharmaceutical development and commercialization.

Negatives

• The company's independent registered public accounting firm's report includes an explanatory paragraph stating substantial doubt about its ability to continue as a going concern beyond August 2025.
• Cash and cash equivalents are extremely low at $112 as of March 31, 2025, coupled with a significant negative working capital of approximately $31.7 million.
• The company has a history of net losses, including $7,735,552 for the quarter ended March 31, 2025, and expects to incur losses for the foreseeable future, with no assurance of achieving profitability.
• Significant outstanding liabilities include $28.4 million in license payments and $16.4 million to third-party suppliers and manufacturers, creating immediate financial pressure.
• Heavy dependence on the successful commercial launch of LYMPHIR, which is not expected until the second half of 2025, and the company has limited direct commercialization experience.
• The company is highly dependent on Citius Pharma for funding and all operational functions, which creates potential conflicts of interest and risks if Citius Pharma ceases support.
• The current offering's estimated net proceeds of $13.65 million are insufficient to cover all immediate liabilities and long-term operational needs, necessitating further capital raises.
• There is no established trading market for the Warrants and Pre-Funded Warrants being sold in this offering, which will limit their liquidity.
• The offering will result in immediate dilution of $3.134 per share to new investors, and future equity issuances are expected to cause further dilution.

Risks

• Substantial doubt about the company's ability to continue as a going concern.
• Requirement for substantial additional funding in the near future, even after this offering, which may not be available on acceptable terms, or at all.
• Heavy dependence on the planned launch and commercial success of LYMPHIR, as it is the only approved product.
• Obligation to make significant milestone and other payments to licensors (Eisai, Dr. Reddys), which could adversely affect profitability.
• Obligation to pay Citius Pharma for services under the A&R Shared Services Agreement and repay a $3,800,111 promissory note.
• History of net losses and expectation to incur losses for the foreseeable future, with no assurance of achieving profitability.
• Risk of material breach or default under license agreements, including failure to make timely payments, which could lead to termination of licenses.
• Exclusive reliance on third parties for formulation and manufacturing, with risks of delays or loss of support due to contractual breaches or non-compliance.
• LYMPHIR may not gain market acceptance among physicians, patients, healthcare payers, or the medical community.
• Inability to create a market for LYMPHIR or future product candidates if marketing, sales, and distribution capabilities are not successfully established.
• Limited operating history to evaluate the ability to successfully commercialize LYMPHIR.
• Highly competitive markets in the pharmaceutical and medical products industries.
• Product revenues may be diminished if LYMPHIR sells for inadequate prices or patients cannot obtain adequate reimbursement.
• Healthcare reform measures could hinder or prevent commercial success.
• Termination, breach by, or conflict with strategic partners could harm the business.
• Reliance on the significant experience of executive management and key personnel, with risks associated with their loss or inability to hire successors.
• Difficulties in managing growth as the organization expands.
• Exposure to product liability claims.
• Uncertainty in obtaining necessary U.S. or foreign regulatory approvals for future product candidates.
• Dependence on protecting intellectual property, with risks of challenges, invalidation, or infringement by third parties.
• Volatility in the market price of Common Stock, with potential for loss of investment.
• Dilution of ownership interests due to future issuance of additional shares or convertible securities.
• Risk of suspension or delisting from Nasdaq if compliance with listing requirements is not maintained.
• If delisted and determined to be a penny stock, trading may become more difficult.
• No intention to list Warrants or Pre-Funded Warrants, limiting their liquidity.
• Board's ability to create new series of preferred stock without stockholder approval could adversely affect common stockholders' rights.
• No history of cash dividends and no expectation to pay them in the foreseeable future.
• Operating results may fluctuate significantly.
• Controlled company status under Nasdaq rules allows reliance on exemptions from certain corporate governance requirements.
• Volatility in share price could lead to securities litigation.
• Anti-takeover provisions in corporate documents and Delaware law could discourage takeovers.
• Incorrect estimates or changes in financial reporting standards could adversely affect results.
• Conflicts of interest may arise from the relationship with Citius Pharma due to shared management and ownership.
• Difficulty replacing corporate functions currently provided by Citius Pharma if they cease support.
• Financial statements may not be indicative of stand-alone operations.
• Citius Pharma's control (92.3% voting power) means its interests may differ from public stockholders.

Future Outlook

The company expects to incur losses for the foreseeable future and will require substantial additional funding beyond August 2025 to support its operations. It plans to commercialize LYMPHIR in the U.S. in the second half of 2025 and is actively evaluating strategic alternatives, including partnerships, joint ventures, mergers, acquisitions, or licensing transactions, to secure necessary resources and maximize shareholder value. The company also intends to pursue additional indications for LYMPHIR and continue investigator-initiated trials for immuno-oncology combination therapies.

Management Comments

• "We expect this offering to be completed not later than two business days following the commencement of this offering and we will deliver all securities to be issued in connection with this offering upon receipt of investor funds received by us."
• "Our management believes that inflation has not had a material effect on our results of operations."
• "The Company believes there is an attractive and growing market for LYMPHIR, estimated to exceed $400 million, that is underserved by existing treatments."
• "The Company is confident that all drug substance and drug product materials meet or will meet specifications as agreed with the FDA."
• "The Company also believes our contract manufacturers have sufficient capacity to support demand for LYMPHIR and any future clinical phase and approved products as our business grows."
• "The Company believes there is an opportunity in the field of immuno-oncology and has undertaken two investigator-initiated trials to evaluate the potential safety and efficacy of LYMPHIR as an immuno-oncology combination therapy."
• "This highlights the therapeutic potential of LYMPHIR plus immune checkpoint inhibitors to be effective in patients who fail prior anti-PD-1/L1 therapy."
• "The Company believes that LYMPHIRs addition to the NCCN guidelines will assist LYMPHIR in obtaining coverage and reimbursement from the Centers for Medicare and Medicaid Services (CMS)."

Industry Context

The company operates in the highly competitive pharmaceutical and medical products industries, which are characterized by costly sales and marketing infrastructures, extensive research efforts, and rapid technological progress. It focuses on developing and commercializing innovative targeted oncology therapies, specifically for Cutaneous T-cell Lymphoma (CTCL), a rare form of non-Hodgkin lymphoma, which it identifies as an underserved market. While several approved targeted therapeutics exist for CTCL, the company highlights their limitations (toxicity, adverse events, limited duration of response), positioning LYMPHIR to address this unmet medical need. The company is also exploring the growing field of immuno-oncology through combination therapies. The broader industry context includes ongoing challenges related to healthcare reform measures, pricing pressures, and the need for robust reimbursement policies for new products.

Comparison to Industry Standards

• LYMPHIR's safety profile from Study E7777-G000-302 is comparable to Study 93-04-11/L4389-11, which served as the basis for the full approval of ONTAK, indicating consistency with a previously approved formulation.
• The pivotal trial of LYMPHIR demonstrated an Objective Response Rate (ORR) of 36.2% (95% CI: 25.0%, 48.7%), with 8.7% achieving Complete Response (CR) and 27.5% achieving Partial Response, meeting the protocol's requirement for the lower bound of the 95% CI to exceed 25%.
• Preliminary Phase 1 trial results for LYMPHIR in combination with pembrolizumab showed an ORR of 27% and a Clinical Benefit Rate (CBR) of 33% among evaluable patients, with a median progression-free survival (PFS) of 57 weeks. Notably, two of the four patients achieving partial remission had failed prior checkpoint inhibitors, suggesting potential efficacy in a challenging patient population compared to standard treatments.
• The company's financial position, characterized by $112 in cash, a negative working capital of approximately $31.7 million, and a going concern warning, is significantly below the financial stability typically expected of a commercial-stage biopharmaceutical company.
• The company's reliance on third-party manufacturing and a shared services agreement with its parent company, Citius Pharma, for all operational functions is a common strategy for smaller biotechnology firms, but it also introduces specific risks related to dependence and potential conflicts of interest not typically seen in fully independent, established companies.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not involved in any litigation that it believes could have a material adverse effect on its financial position or results of operations.
• There is no action, suit, proceeding, inquiry, or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the company's executive officers, threatened against or affecting the company or its officers or directors in their capacities as such.

Related Party Transactions

• Citius Pharma provides all operational functions, systems, and infrastructure to Citius Oncology through an Amended and Restated Shared Services Agreement (A&R Shared Services Agreement).
• Citius Oncology pays Citius Pharma an aggregate quarterly fee of approximately $940,000 for these services, plus reimbursement for all reasonable out-of-pocket costs and expenses.
• For the year ended September 30, 2024, Citius Pharma charged Citius Oncology $1,846,202 for general and administrative payroll reimbursement, $1,963,630 for research and development payroll reimbursement, and $121,570 for shared office space use.
• Citius Pharma has historically funded Citius Oncology's expenditures, resulting in $14,270,648 due to related party for the year ended September 30, 2024, and $4,352,858 for the six months ended March 31, 2025.
• In connection with the Merger, Citius Pharma contributed $33,180,961 in intercompany receivables to Citius Oncology's additional paid-in capital.
• Citius Pharma made cash contributions of $3,827,944 to Citius Oncology's capital for merger-related transactions.
• Citius Pharma advanced $3,800,111 to Citius Oncology via an unsecured, non-interest-bearing promissory note dated August 16, 2024, repayable in full if Citius Oncology raises at least $10 million in financing.
• Citius Pharma is a guarantor of Citius Oncology's payment obligations under the license agreements for LYMPHIR.
• Most of Citius Oncology's executive officers and directors also serve as directors and/or employees of Citius Pharma, creating potential conflicts of interest.
• Citius Pharma holds approximately 92.3% of Citius Oncology's outstanding common stock, making Citius Oncology a controlled company, which means Citius Pharma's interests may not always align with those of public stockholders.

Stakeholder Impact

• Shareholders face significant dilution from the current offering and potential future equity raises, and there is a high risk of losing their entire investment due to the company's going concern uncertainty and substantial losses. Citius Pharma's majority ownership means its interests may not always align with public shareholders.
• Employees (indirectly, as the company has no direct employees and relies on Citius Pharma's staff) may experience uncertainty due to the company's financial instability, though the shared services agreement provides some operational continuity. Future growth will require attracting and retaining qualified personnel.
• Customers (physicians, patients, healthcare payers) may benefit from LYMPHIR as a new treatment option for CTCL, an underserved market. However, market acceptance and reimbursement levels are uncertain, which could impact patient access.
• Suppliers and manufacturers, particularly those involved in drug substance and finished product supply, face risks related to the company's ability to make timely payments on its significant outstanding liabilities and minimum purchase commitments.
• Creditors face high risk due to the company's severe financial distress, including extremely low cash, negative working capital, and substantial outstanding liabilities, as highlighted by the going concern warning.

Next Steps

• Complete the current public offering of common stock and warrants to raise estimated net proceeds of $13.65 million.
• Repay the $3,800,111 promissory note to Citius Pharma if the gross proceeds from the current offering equal or exceed $10 million.
• Make scheduled payments to Eisai: $2,535,318 by July 15, 2025, followed by four monthly payments of $2,350,000, and a final payment of $2,197,892 by December 15, 2025.
• Proceed with the commercial launch of LYMPHIR in the U.S., expected in the second half of 2025.
• Establish and expand marketing, sales, and distribution capabilities for LYMPHIR, including utilizing Innovation Partners.
• Continue two investigator-initiated immuno-oncology trials for LYMPHIR at the University of Minnesota and the University of Pittsburgh Medical Center.
• Raise substantial additional capital to support operations beyond August 2025.
• Continue evaluating strategic alternatives aimed at maximizing shareholder value, such as partnerships, joint ventures, mergers, acquisitions, or licensing transactions.
• Maintain compliance with Nasdaq listing requirements to avoid potential delisting.

Key Dates

Recommendation

Keywords

Citius Oncology, LYMPHIR, CTCL, Cutaneous T-cell Lymphoma, Oncology, Biopharmaceutical, SEC Filing, S-1/A, Public Offering, Warrants, Pre-Funded Warrants, FDA Approval, Going Concern, Capital Raise, Nasdaq Compliance, Drug Commercialization, Rare Disease, Immuno-oncology, Clinical Trials, Financial Health, Dilution, Citius Pharma, Milestone Payments, Intellectual Property